ArticleFrontiers in medicine2025
A bibliometric analysis of the current state and future directions of osteoporosis pharmacological treatment.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Osteoporosis is a major health threat, particularly with the aging population in China. Medication remains a cornerstone of management, and bibliometric analysis can provide insights into current research status and future directions. Methods: Relevant literature from the Science Citation Index Core Collection (2015-2024) was analyzed using bibliometric methods. Visual maps were generated with Citespace 6.3R3 and VOSviewer 1.6.19 to assess research trends and hotspots. Results: A total of 2,738 publications were included, showing a steady growth in research since 2015. The United States led in output, with the University of Toronto as the most productive institution. Brandi, Maria Luisa, and Kanis JA were the most influential authors, while Osteoporosis International and The Journal of Bone and Mineral Research were the most cited journals. Key themes included extracellular vesicles, romosozumab, bisphosphonates, and breast cancer, with recent attention on targeted drug delivery, treatment efficacy, and medication management. Emerging keywords from 2022 to 2023, such as exosomes, inflammation, and osteogenic differentiation, reflected advances in therapeutic mechanisms and clinical applications. Conclusion: Future research will likely emphasize targeted drug delivery, clinical efficacy and safety, and molecular targeted therapies, with the development of new anti-osteoporosis drugs remaining a key focus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.